By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Nanopore today said that it has raised £25 million ($41 million) in a private placement of ordinary shares.

The Oxford, UK-based nanopore sequencing firm said that it would use the funds to support further development, external validation, and production capabilities for its technology in DNA sequencing and protein analysis applications. The firm's platform technology, GridION, consists of a scalable, modular instrument and consumable cartridge.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Jun
12
Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.